{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:30:01Z","timestamp":1768905001822,"version":"3.49.0"},"reference-count":16,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2004,11,4]],"date-time":"2004-11-04T00:00:00Z","timestamp":1099526400000},"content-version":"vor","delay-in-days":2560,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[1997,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background:<\/jats:bold> Elston and Russell discovered a difference in the biological potency of the English formulation of botulinum toxin type A or BTX\u2010A (Dysport) and the American formulation (Botox). Potency of both is expressed in LD50 mouse units, but because of assay differences, these units are not equivalent. Since the first warning by Quinn and Hallet on the clinical importance of this issue, it has been impossible to reach a consensus on the conversion factor for the potency of these formulations.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> To test the hypothesis that the conversion factor\nfor the clinical potency of Dysport to Botox is approximately 4.1. DYSBOT is an acronym that results from adding \u201cDYS\u201d from Dysport with \u201cBOT\u201d from Botox.<\/jats:p><jats:p><jats:bold>Patients and Methods:<\/jats:bold> Design: A single\u2010blind, randomized, parallel comparison. A total of 91 patients with blepharospasm or hemifacial spasm were randomized to treatment with Dysport or Botox using a fixed potency ratio of 4:1. <jats:italic>Clinical evaluations<\/jats:italic>: The patients were evaluated at baseline (day of the treatment), 1 month after treatment, and whenever the effect was judged to be fading. Objective and functional rating scales were used as quantitative measures of the change in clinical status. Adverse reactions were collected using a systematic questionnaire.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Using this ratio between products, both Dysport and\nBotox groups produced similar clinical efficacy and tolerability. For patients showing a positive response without the need of a booster, the duration of effect was 13.3 \u00b1 5.9 weeks for the Dysport group and 11.2 \u00b1 5.8 weeks for the Botox group. Of 48 patients, 11 (23%) needed booster treatment in the Dysport group compared with five (12%) of 43 in Botox group. Adverse events were noted in 24 (50%) of 48 patients in the Dysport group and 20 (47%) of 43 of the Botox\u2010treated group.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Using a 4:1 conversion ratio for Dysport and Botox, similar results were obtained for the two treatments in an appropriately powered study, suggesting that this conversion factor is a good estimate of their comparative clinical potencies.<\/jats:p>","DOI":"10.1002\/mds.870120627","type":"journal-article","created":{"date-parts":[[2005,5,28]],"date-time":"2005-05-28T20:33:54Z","timestamp":1117312434000},"page":"1013-1018","source":"Crossref","is-referenced-by-count":154,"title":["DYSBOT: A single\u2010blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A\u2014Dysport and Botox\u2014assuming a ratio of 4:1"],"prefix":"10.1002","volume":"12","author":[{"given":"Cristina","family":"Sampaio","sequence":"first","affiliation":[]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Fernanda","family":"Sim\u00f5es","sequence":"additional","affiliation":[]},{"given":"Maria J.","family":"Rosas","sequence":"additional","affiliation":[]},{"given":"Marina","family":"Magalh\u00e3es","sequence":"additional","affiliation":[]},{"given":"Ana P.","family":"Correia","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio","family":"Bastos\u2010Lima","sequence":"additional","affiliation":[]},{"given":"Rairnundo","family":"Martins","sequence":"additional","affiliation":[]},{"given":"Alexandre","family":"Castro\u2010Caldas","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2004,11,4]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.290.6485.1857"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92551-8"},{"key":"e_1_2_1_4_2","first-page":"719","article-title":"Potency equivalence of botulinum toxin preparations","volume":"87","author":"Pickett AM","year":"1994","journal-title":"J R Soc Med"},{"key":"e_1_2_1_5_2","first-page":"571","article-title":"Botulinum toxin potency: a mystery resolved by the median paralysis unit","volume":"87","author":"Borodic GE","year":"1994","journal-title":"J R Soc Med"},{"key":"e_1_2_1_6_2","first-page":"307","article-title":"Botulinum toxin","volume":"87","author":"Sesardic D","year":"1994","journal-title":"J R Soc Med"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90732-3"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91806-6"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90263-5"},{"key":"e_1_2_1_10_2","unstructured":"SampaioC FerreiraJJ Castro\u2010CaldasA.Clinical efficacy of botulinum toxin: American versus British toxin [Abstract]. In: Proceedings of the joint meeting of the British and Portuguese Societies of Neurology Lisbon November1992."},{"key":"e_1_2_1_11_2","first-page":"241","volume-title":"Quantification of Neurologic Deficit","author":"Fahn S","year":"1989"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.59.1.102"},{"key":"e_1_2_1_13_2","first-page":"387","article-title":"Comparison of dosage effects between the American and British botulinum toxin A products in the treatment of spasmodic dysphonia [Abstract]","volume":"10","author":"Whurr R","year":"1995","journal-title":"Mov Disord"},{"key":"e_1_2_1_14_2","unstructured":"DurifF.Clinical bioequivalence of current commercial preparations of botulinum toxin [Abstract]. In: Second European botulinum toxin symposium Cannes March 17\u20139 1995."},{"key":"e_1_2_1_15_2","first-page":"90","volume-title":"Handbook of Botulinum Toxin Treatment","author":"Elston J","year":"1995"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.59.3.309"},{"key":"e_1_2_1_17_2","first-page":"199","volume-title":"Therapy with Botulinum Toxin","author":"Dutton JJ","year":"1994"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.870120627","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.870120627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:38:44Z","timestamp":1760956724000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.870120627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,11]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1997,11]]}},"alternative-id":["10.1002\/mds.870120627"],"URL":"https:\/\/doi.org\/10.1002\/mds.870120627","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,11]]}}}